Besifloxacin
From Wikipedia, the free encyclopedia
 |
|
|---|---|
| Systematic (IUPAC) name | |
| 7-[(3R) -3-aminoazepam- 1-yl]- 8-chloro- 1-cyclopropyl- 6-fluoro- 4-oxo- 1,4- dihydroquinoline- 3-carboxylic acid | |
| Clinical data | |
| Trade names | Besivance |
| AHFS/Drugs.com | monograph |
| MedlinePlus | a610011 |
| Licence data | US FDA:link |
| Pregnancy cat. | ? |
| Legal status | ℞-only (US) |
| Routes | Opthalmic |
| Identifiers | |
| CAS number | 141388-76-3 |
| ATC code | S01AX23 |
| UNII | BFE2NBZ7NX  |
| ChEMBL | CHEMBL1201760 |
| Chemical data | |
| Formula | C19H21ClFN3O3 |
Besifloxacin (INN/USAN) is a fourth-generation fluoroquinolone antibiotic. The marketed compound is besifloxacin hydrochloride. It was developed by SSP Co. Ltd., Japan, and designated SS734. SSP licensed U.S. and European rights to SS734 for ophthalmic use to InSite Vision Incorporated (OTCBB: INSV) in 2000. InSite Vision developed an eye drop formulation (ISV-403) and conducted preliminary clinical trials before selling the product and all rights to Bausch & Lomb in 2003.[1]
The eye drop was approved by the United States Food and Drug Administration (FDA) on May 29, 2009 and marketed under the trade name Besivance.[2]
Besifloxacin has been found to inhibit production of pro-inflammatory cytokines in vitro.[3]
[edit] See also
[edit] References
- ^ "InSite Vision Reaches Agreement to Sell ISV-403 to Bausch & Lomb" (Press release). InSite Vision. 2003-12-19. http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/12-19-2003/0002079091&EDATE=. Retrieved 2009-08-15.
- ^ "Bausch & Lomb Receives FDA Approval of Besivance, New Topical Ophthalmic Antibacterial for the Treatment of Bacterial Conjunctivitis (“Pink Eye”)" (Press release). Bausch & Lomb. 2009-05-29. http://www.bausch.com/en_US/corporate/corpcomm/news/besivance_approval.aspx. Retrieved 2009-05-29.
- ^ Zhang JZ, Ward KW (January 2008). "Besifloxacin, a novel fluoroquinolone antimicrobial agent, exhibits potent inhibition of pro-inflammatory cytokines in human THP-1 monocytes". J. Antimicrob. Chemother. 61 (1): 111–6. doi:10.1093/jac/dkm398. PMID 17965029.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
This systemic antibacterial-related article is a stub. You can help Wikipedia by expanding it. |
